Targeting CD30 in malignant tissues: Challenges in detection and clinical applications

Pathobiology

Volumn 80, Issue 5, 2013, Pages 252-258

  Wasik, Mariusz A ^a   Jimenez, Gretchen S ^b   Weisenburger, Dennis D ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Upside Endeavors   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Anaplastic large cell lymphoma; CD30; Flow cytometry; Immunohistochemistry

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; FORMALDEHYDE; PARAFFIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIGEN EXPRESSION; ANTIGEN RETRIEVAL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOMATOID PAPULOSIS; MOLECULAR WEIGHT; MONOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN TARGETING; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TISSUE FIXATION; CANCER DIAGNOSIS; CANCER TISSUE; DIAGNOSTIC PROCEDURE; HUMAN TISSUE; PROTEIN EXPRESSION; PROTEIN FAMILY; STANDARDIZATION;

ANTIGENS, CD30; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIXATIVES; FLOW CYTOMETRY; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS; OBSERVER VARIATION; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84877852205     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000347192     Document Type: Article

References (24)

1. Falini B, Pileri S, Pizzolo G, Durkop H, Flen-ghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfam-ily as a tool for diagnosis and immunothera-py. Blood 1995; 85:1-14.
2. Duvic M: CD30+ neoplasms of the skin. Curr Hematol Malig Rep 2011;6:245-250.
3. de Leval L, Gaulard P: CD30+ lymphoprolif-erative disorders. Haematologica 2010; 95: 1627-1630.
4. Stein H, Mason DY, Gerdes, J, et al: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lym-phoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-858. (Pubitemid 15242469)
5. Granados S, Hwang ST: Roles for CD30 in the biology and treatment of CD30 lymphoprolif-erative diseases. J Invest Dermatol 2004;122: 1345-1347. (Pubitemid 38757213)
6. Tian ZG, Longo DL, Funakoshi S, et al: In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res 1995; 55:5335-5341.
7. Younes A, Bartlett NL, Leonard JP, et al: Bren-tuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-1821.
8. Younes A, Yasothan U, Kirkpatrick P: Bren-tuximab vedotin. Nat Rev Drug Discov 2012; 11:19-20.
9. Furtado M, Rule S: Emerging pharmacother-apy for relapsed or refractory Hodgkin's lym-phoma: focus on brentuximab vedotin. Clin Med Insights Oncol 2012;6:31-39.
10. Garcia CF, Swerdlow SH: Best practices in contemporary diagnostic immunohisto-chemistry: penal approach to hematolym-phoid proliferations. Arch Pathol Lab Med 2009; 133:756-765.
11. Wilkins BS: Pitfalls in lymphoma pathology: avoiding errors in diagnosis of lymphoid tissues. J Clin Pathol 2011; 64:466-476.
12. Carson F: Fixation and processing; in Brown RW (ed): Histological Preparations: Common Problems and Their Solutions. North-field, CAP Press and Publications, 2009.
13. Bussolati G, Leonardo E: Technical pitfalls potentially affecting diagnosis in immunohis-tochemistry. J Clin Pathol 2008;61:1184-1192.
14. Dunphy CH: Applications of flow cytometry and immunohistochemistry to diagnostic he-matopathology. Arch Pathol Lab Med 2004; 128:1004-1022.
15. de Tute RM: Flow cytometry and its use in the diagnosis and management of lymphoid malignancies. Histopathology 2011;58:90-105.
16. Sewell WA, Smith SA: Polychromatic flow cy-tometry in the clinical laboratory. Pathology 2011; 43:580-591.
17. NordiQC: Assessment Run 31 2011: CD30. Full data available at: http://www.nordiqc. org/Run-31-G1/Assessment/assessment-31-CD30.htm (accessed March 14, 2012).
18. Goldstein NS, Hewitt SM, Taylor CR: Recommendations for improved standardization of immunohistochemistry. Appl Immunohisto-chem Mol Morphol 2007; 15:124-133. (Pubitemid 46828218)
19. Torlakovic EE, Riddell R, Banerjee D, et al: Canadian Association of Pathologists-Association Canadienne des Pathologistes National Standards Committee/Immunohistochem-istry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol 2010; 133:354-365.
20. O'Leary TJ: Standardization in immunohis-tochemistry. Appl Immunohistochem Mol Morphol 2001; 9:3-8.
21. Shi SR, Liu C, Taylor CR: Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. J Histochem Cytochem 2007; 55:105-109. (Pubitemid 46147687)
22. Taylor CR: Quantifiable internal reference standards for immunohistochemistry. Appl Immunohistochem Mol Morphol 2006; 14: 253-259.
23. Falini B, Bolognesi A, Flenghi L, et al: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339:1195-1196.
24. Kempf W, Pfaltz K, Vermeer M, et al: EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 13:4024-4035.